In the BioHarmony Drug Report Database

"Preview" Icon

Relugolix

Orgovyx, Ryeqo (relugolix) is a small molecule pharmaceutical. Relugolix was first approved as Orgovyx on 2020-12-18. It has been approved in Europe to treat leiomyoma. It is known to target gonadotropin-releasing hormone receptor. Orgovyx’s patents are valid until 2037-09-29 (FDA).

 

Trade Name

 

Ryeqo
 

Common Name

 

relugolix
 

ChEMBL ID

 

CHEMBL1800159
 

Indication

 

leiomyoma
 

Drug Class

 

Gnrh receptor antagonists (nonpeptide)

Image (chem structure or protein)

Relugolix structure rendering